Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Katherine Cox

Nurse Practitioner, Family Barboursville, WV Nurse Practitioner

NPI 1952858011 CMS profile 10859542

6475 Farmdale Rd, Barboursville, WV 25504

Open in the dashboard

General payments

$6,452

421 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Katherine Cox of Barboursville, WV is reported in the CMS Open Payments database as having received $6,452 across 421 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $491 26
2024 General $607 43
2023 General $991 57
2022 General $1,478 97
2021 General $2,886 198

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Katherine Cox
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Katherine Cox were reported at $491. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Katherine Cox Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $2,886 $124 $35–$379 $132
2022 $1,478 $141 $44–$430 $149
2023 $991 $154 $49–$476 $160
2024 $607 $165 $51–$504 $164
2025 $491 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,160 96 payments
  2. Novo Nordisk Inc $1,002 70 payments
  3. Pfizer Inc. $683 41 payments
  4. Biohaven Pharmaceuticals, Inc. $428 11 payments
  5. GlaxoSmithKline, LLC. $378 24 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $334 30 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $272 20 payments
  8. Astellas Pharma US Inc $262 13 payments
  9. AstraZeneca Pharmaceuticals LP $228 10 payments
  10. Merck Sharp & Dohme Corporation $197 9 payments
  11. Other $1,509 97 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,420 420 payments
  2. Education $32 1 payment
Products named General payments · program years 2021–2025
  1. RYBELSUS $901 65 payments
  2. Ozempic $827 63 payments
  3. VRAYLAR $586 52 payments
  4. NURTEC ODT $488 15 payments
  5. UBRELVY $355 28 payments
  6. PREVNAR 13 $307 19 payments
  7. QULIPTA $294 21 payments
  8. PREVNAR 20 $285 16 payments
  9. TRELEGY ELLIPTA $283 18 payments
  10. COMIRNATY $217 12 payments
  11. Other $4,702 273 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 108 drugs

Part D claims

5,563

Median for Nurse Practitioner: 389

Drug cost

$353,224

Median for Nurse Practitioner: $21,885

Branded share of claims

17.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 83 $98,638
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 34 $39,280
Eliquis Apixaban Brand 33 $30,824
Tradjenta Linagliptin Brand 32 $30,369
Januvia Sitagliptin Phosphate Brand 20 $26,250
Jardiance Empagliflozin Brand 16 $24,275
Mounjaro Tirzepatide Brand 11 $11,298
Vascepa Icosapent Ethyl Brand 24 $10,948
Toujeo Solostar Insulin Glargine,hum.Rec.Anlog Brand 15 $10,840
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 13 $8,250

The 10 drugs with the highest cost, of 108 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$31,479

Medicare's payments for the services billed

Medicare patients

170

Average age 72

Services billed

669

113 women, 57 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 39%
Diabetes 31%
Ischemic heart disease 23%
Chronic kidney disease 22%
COPD 22%
Atrial fibrillation 18%
Depression 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $182
$182 — —
QULIPTA
  • AbbVie, Inc. $60
$60 — —
UBRELVY
  • AbbVie, Inc. $42
$42 — —
Veozah
  • Astellas Pharma US Inc $41
$41 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $32
$32 34 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

421 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record